Mexidol^® FORTE 250: the Expert Council members’ opinion of the therapeutic potential in the treatment of patients with cerebrovascular disease

In September, with the support of Vectorpharm LLC, an Expert Council of Neurologists and Clinical Pharmacologists was held, which was attended by leading Russian experts from Moscow, St. Petersburg, Novosibirsk, Volgograd, Kazan, Yaroslavl and other cities of Russia. The main topic was the discussion of medical application of a new form of domestic reference drug Mexidol^® FORTE 250 in the dosage of 250 mg. The Council chairman and moderator was Professor A.I. Fedin.

The Council members emphasized the practical relevance and social significance of the new drug form – Mexidol^® FORTE 250, the only active substance drug Ethylmethylhydroxypyridine succinate with a double dosage to be taken per os, which will allow to increase patients’ adherence to therapy due to the convenience of taking medicines (3 tablets a day instead of 6).

At the end of the Expert Council meeting, the experts concluded that the use of Mexidol^® and Mexidol^® FORTE 250 was clinically grounded by the practical work of each doctor treating patients with cerebrovascular disorders, due to the proved high efficacy and safety of drugs. Particular importance is attached to therapy sequence, optimal dosages, treatment duration: thus, to achieve the maximum therapeutic effect, treatment should be started with intravenous injections of Mexidol^® 10 ml (500 mg) for 10-15 days followed by tablet form of Mexidol^® FORTE 250 mg 3 times a day for 4-6 weeks.

In conclusion, we can note that each report was extremely useful from the scientific and clinical points of view and caused the audience’s interest.